Y. Sheytanov, I. Sheytanov and Ts. Petranova. USE OF HUMIRA (ADALIMUMAB) IN PATIENTS WITH RHEUMATOID ARTHRITIS

Summary. Humira (Adalimumab) is a representative of the so called biological agents. It is a recombinant human monoclonal antibody directed towards TNF, a key cytokine in the pathogenesis of rheumatoid arthritis (RA). Humira neutralizes its biological function by blocking its interaction with the TNF receptors on the cell surface. In this review, the international experience of Humira use in patients with active rheumatoid arthritis is presented. Its therapeutic efficacy and safety in combined use with Methotrexate and other disease-modifying antirheumatic agents as well as in monotherapy are shown. Presented are the therapeutic effect of this biological drug on the main clinical manifestations and the inflammatory activity in patients with RA, the influence on the roentgenologic features, and the physical function. It is concluded that Humira (Adalimumab) is an efficient and reliable therapeutic alternative in patients with inadequate response to the standard antirheumatic treatment.

Key words: Adalimumab, TNF, rheumatoid arthritis, therapeutic efficacy
M. Geneva-Popova. Research of artralgia syndrome in AHB and AHC
M. Geneva-Popova. Articular manifestations in HIV and AIDS
M. Georgieva and B. Varbanova. Systemic manifestations of inflammatory bowel diseases in childhood
N. Kapandzhieva. A clinical case of primary antiphospholipid syndrome
R. Karalilova, A. Batalov, R. Nestorova and D. Penev. Early diagnosis of spondyloarthropathies and sonographic evaluation of enthesopathies
E. Kostova, B. Varbanova, V. Yotova, D. Blisnakova, L. Marinov and P. Shivachev. Generalized osteoporosis and multiple aseptic necroses in a patient with juvenile idiopathic arthritis
S. Lambova, St. Kuzmanova, Y. Nikolova and R. Ivanova. Nailfold capillaroscopic findings in systemic sclerosis: relationship with clinical manifestation and plasma endothelin-1 levels
S. Monov, A. Ivanov and B. Milev. MRI changes in patients with systemic lupus erythematosus
S. Monov and R. Rashkov. Intraarticular application of Hyalgan in patients with hip joint lesions
S. Monov, R. Rashkov and D. Monova. Oxaprozin in patients with gout
S. Monov, F. Martinova and D. Monova. Antithrombin III in patients with systemic lupus erythematosus
D. Monova and S. Monov. Urinary bladder dysfunction in women with systemic lupus erythematosus
R. Nestorova, E. Naredo and A. Batalov. Sonographic evaluation of Plica syndrome
R. Nestorova, S. Zheleva and S. Monov. Biphosphonates and osteonecrosis of the jaw
R. Rashkov and S. Monov. Catastrophic antiphospholipid syndrome in patients with systemic lupus erythematosus
V. Restkova. New aspects in the treatment of fibromyalgia syndrome
V. Restkova and R. Rashkov. Fibromyalgia syndrome and our clinical experience
G. Slavcheva and S. Monov. A case of Takayasu disease with central nervous system lesions
R. Stoilov and M. Ivanova. Use of stem cells in patients with rheumatoid polyarthritis
Zl. Stoyneva. Laser Doppler flowmetry and Raynaud’s phenomenon
Zl. Stoyneva. Capillaroscopy in rheumatology practice
V. Todorova, Hr. Dimitrov, L. Chochkova, A. Chapanova and D. Pechilkov. Juvenile local scleroderma – characteristics and evolution on occasion of observed cases
D. Yaneva, D. Karastatev. B. Oparanov and T Shivaceva. Tocilizumab – safety and tolerability in 48 patients with active rheumatoid arthritis

REVIEWS
Y. Sheytanov, I. Sheytanov and Ts. Petranova. Use of Humira (Adalimumab) in patients with rheumatoid arthritis